MAP2K7 and cancer: In heterogeneous tumors, with a mix of plastic epithelial and mesenchymal cancer cells, net tumor killing requires drug combinations that preferentially target the vulnerabilities of each subpopulation (e.g., MEK inhibitors and CDK4 inhibitors) and prevent the outgrowth of resistant cells.